Dermatomyositis (DM) is a rare chronic idiopathic inflammatory myopathy, characterized by symmetrical proximal muscle involvement and typical skin lesions. The incidence is approximately 5/1,000,000 population. DM occurs in all races, twice as often in females. It is also not rare in childhood, when it is known as juvenile dermatomyositis (JDM). In about 10% of patients the cutaneous changes characteristic of DM are not associated with muscle disease (amyopathic DM). DM of adults is associated in about 3o% of patients with internal malignancies. The immunogenetics of DM is not homogeneous.


Idiopathic Inflammatory Myopathy Juvenile Dermatomyositis Internal Malignancy Cutaneous Change Muscle Enzyme Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jablonska S, Chorzelski TP, Blaszczyk Met al (1993) Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 10: 457–472CrossRefGoogle Scholar
  2. 2.
    Park JH, Vital TL, Ryder NM et al (1994) Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 37: 736–746PubMedCrossRefGoogle Scholar
  3. 3.
    Palier AS (1996) The use of pulse corticosteroid therapy for juvenile dermatomyositis. Pediatr Dermatol 13: 347–348CrossRefGoogle Scholar
  4. 4.
    Joffe NIM, Love LA, Leff RI et al (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 94: 379–387PubMedCrossRefGoogle Scholar
  5. 5.
    Dalakas MC (1994) Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 6: 594–601CrossRefGoogle Scholar
  6. 6.
    Kasteler JS, Callen JP (1997) Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol 36: 67–71PubMedCrossRefGoogle Scholar
  7. 7.
    Oddis CV (1991) Therapy for myositis. Curr Opin Rheumatol 3: 919–924PubMedCrossRefGoogle Scholar
  8. 8.
    Sinoway PA, Callen JP (1993) Chlorambucil: an effective corticosteroid sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 36: 319–324PubMedCrossRefGoogle Scholar
  9. 9.
    Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993–2000PubMedCrossRefGoogle Scholar
  10. 10.
    Mattheou-Vakali G, Ioannides D, Lazaridou E et al (1997) Dermatomyositis sine myositis in five cases. J Eur Acad Dermatol Venereol 18: 208–211CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • S. Jablonska

There are no affiliations available

Personalised recommendations